TSE:4552Pharmaceuticals
JCR Pharmaceuticals (TSE:4552) One Off Gain Driven Profit Challenges Bullish Earnings Narratives
JCR Pharmaceuticals (TSE:4552) has reported its FY 2026 results with fourth quarter revenue of ¥9,966 million and basic EPS of ¥3.56, alongside trailing twelve month revenue of ¥40,319 million and basic EPS of ¥17.86 that mark a clear shift from prior losses implied in earlier periods. The company has seen quarterly revenue move from ¥7,192 million in FY 2025 Q4 to ¥8,569 million in FY 2026 Q1, ¥12,793 million in Q2 and ¥8,991 million in Q3. Basic EPS has ranged from a loss of ¥34.28 in FY...